DAPOXETINE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H23NO
Molecular Weight	305.4134
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3

InChI

InChIKey=USRHYDPUVLEVMC-FQEVSTJZSA-N

InChI=1S/C21H23NO/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21/h3-14,20H,15-16H2,1-2H3/t20-/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.medsafe.govt.nz/Profs/Datasheet/p/Priligytab.pdf

Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor (SSRIs). In addition, dapoxetine inhibits voltage-dependent K+ (Kv) channels in a dose-, time-, use-, and state (open)-dependent manner, independent of serotonin reuptake inhibition. Dapoxetine is indicated for the treatment of premature ejaculation (PE) in men 18 to 64 years of age, who have all of the following: persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes; and marked personal distress or interpersonal difficulty as a consequence of PE; and poor control over ejaculation. The mechanism of action of dapoxetine in premature ejaculation is presumed to be linked to the inhibition of neuronal reuptake of serotonin and the subsequent potentiation of the neurotransmitter's action at pre- and post-synaptic receptors. The most common effects when taking dapoxetine are nausea, dizziness, dry mouth, headache, diarrhea, and insomnia.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-gated potassium channel 17 Target ID: CHEMBL2362996 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28058743	Inhibitor 8504		2.68 µM [IC50]
Serotonin transporter 183 Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16430636	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Premature ejaculation 3 Sources: http://www.medsafe.govt.nz/Profs/Datasheet/p/Priligytab.pdf	Primary		Approved 8583	PRILIGY Approved Use INDICATIONS. PRILIGY is indicated for the treatment of premature ejaculation (PE) in men 18 to 64 years of age, who have all of the following: persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes; and marked personal distress or interpersonal difficulty as a consequence of PE; and poor control over ejaculation.

C_max

Value	Dose	Analyte	Population
269 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33528113/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
261 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33528113/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
413 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33528113/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
369 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33528113/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
338 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16920897/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
310 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16920897/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
443 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16920897/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
398 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16920897/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
297 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16490806/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
349 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16490806/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
498 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16490806/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
596 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16490806/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
204 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
259 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
241 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
272 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
252 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
396 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
421 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
403 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
488 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
439 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
1179 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33528113/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1531 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33528113/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
2532 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33528113/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2626 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33528113/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
2040 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16920897/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2280 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16920897/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2190 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16920897/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2450 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16920897/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
1110 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16490806/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1550 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16490806/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2070 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16490806/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2950 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16490806/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1078 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1162 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
980 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1200 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1028 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2022 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2251 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1792 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2238 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1954 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
16.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33528113/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33528113/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
18.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33528113/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33528113/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
17.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16920897/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
26 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16920897/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
16.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16920897/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16920897/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
18.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16490806/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
21.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16490806/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
14.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
16.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
16.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20097934/	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DAPOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% REVIEW https://pubmed.ncbi.nlm.nih.gov/16430636/ \| https://pubmed.ncbi.nlm.nih.gov/32485631/			DAPOXETINE plasma	Homo sapiens

Doses

Dose	Population	Adverse events
60 mg 1 times / day multiple, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19878447/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/19878447/	Disc. AE: Nausea, Dizziness... AEs leading to discontinuation/dose reduction: Nausea (2.5%) Dizziness (1.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/19878447/

AEs

AE	Significance	Dose	Population
Dizziness	1.7% Disc. AE	60 mg 1 times / day multiple, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19878447/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/19878447/
Nausea	2.5% Disc. AE	60 mg 1 times / day multiple, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19878447/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/19878447/

PubMed

Title	Date	PubMed
Pharmacokinetics of dapoxetine hydrochloride in healthy Chinese, Japanese, and Caucasian men.	2010-12	20097934
[Dapoxetine in treatment of premature ejaculation: a systematic review].	2010-08-18	20721257
Counterfeit dapoxetine sold on the Internet contains undisclosed sildenafil.	2010-08	20497263
Dapoxetine: in premature ejaculation.	2010-07-30	20614950
Available and future therapies for premature ejaculation.	2010-07	20683504
Dapoxetine for premature ejaculation.	2010-07	20540653
Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials.	2010-06	20412423
Validity of the patient-reported Clinical Global Impression of Change as a measure of treatment response in men with premature ejaculation.	2010-06	20367770
Organic vs. psychogenic? The Manichean diagnosis in sexual medicine.	2010-05	20537061
Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation.	2010-05	20189712
The dapoxetine paradox.	2010-04	20151958
[Therapy for male patients with sexual dysfunction].	2010-03	20235039
Recent advances in the treatment of premature ejaculation.	2010-02-18	20368901
Dapoxetine. Premature ejaculation: not worth the risk.	2010-02	20455331
Premature ejaculation: treatment update.	2010-02	20089991
Highly efficient, enantioselective syntheses of (S)-(+)- and (R)-(-)-dapoxetine starting with 3-phenyl-1-propanol.	2010-01-01	19957926
Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine.	2010-01	19878447
Challenges in the pharmacotherapy of urogenital disorders.	2010	21811458
Isolation and structural elucidation of dapoxetine as an adulterant in a health supplement used for sexual performance enhancement.	2009-12-05	19574010
Dapoxetine: a novel treatment for premature ejaculation.	2009-09	19956808
Central regulation of ejaculation and the therapeutic role of serotonergic agents in premature ejaculation.	2009-07	19579174
[Premature ejaculation].	2009-06	19557470
Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects.	2009-06	19389877
Dapoxetine debate and conflict of interest.	2009-05	19453934
Editorial comment on: Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries.	2009-04	19195773
Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries.	2009-04	19195772
[Efficacy and safety of selective serotonin re-uptake inhibitors in the treatment of premature ejaculation: a systematic evaluation].	2009-03	19452699
Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial.	2009-03	19021601
The Premature Ejaculation Profile: validation of self-reported outcome measures for research and practice.	2009-02	18793300
MMIX: annus festine lente?	2009-01	19076970
Emerging treatments for premature ejaculation: focus on dapoxetine.	2009	19557098
Effect of dapoxetine on the pharmacokinetics and hemodynamic effects of tamsulosin in men on a stable dose of tamsulosin.	2008-12	18832488
Rational use of dapoxetine for the treatment of premature ejaculation.	2008-10	18787563
Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine.	2008-09	18647300
The pharmacological treatment of premature ejaculation.	2008-09	18485043
Re: François Giuliano, Donald L. Patrick, Hartmut Porst, et Al. for the 3004 study group. Premature ejaculation: results from a five-country European observational study. Eur urol 2008;53:1048-57.	2008-06	18262333
Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study.	2008-05	17625501
Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case.	2008-04	18371047
Regarding Waldinger and Schweitzer's "premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case".	2008-04	18371046
Dapoxetine and paroxetine for the treatment of premature ejaculation.	2007-10-03	17909314
Dapoxetine in the treatment of premature ejaculation.	2007-10-03	17909313
Interview with Dr François Giuliano (by Christine McKillop). New avenues in the pharmacological treatment of premature ejaculation.	2007-10	17646046
W is for Wilbert's wee willy (which tends to go off prematurely).	2007-09-25	17893357
The majority of men with lifelong premature ejaculation prefer daily drug treatment: an observation study in a consecutive group of Dutch men.	2007-07	17627747
Selective serotonin reuptake inhibitors in the treatment of premature ejaculation.	2007-06-05	17624269
Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation.	2007-06	18360636
[Update of pharmacotherapy for premature ejaculation].	2007-05	17569265
Premature ejaculation.	2007-04	19675782
New agents in the treatment of premature ejaculation.	2006-12	19412497
Pharmacologic treatment of rapid ejaculation: levels of evidence-based review.	2006-09	18666749

Patents

Sample Use Guides

In Vivo Use Guide

The recommended starting dose for all patients is 30 mg, taken as needed approximately 1 to 3 hours prior to sexual activity. If the effect of 30 mg is insufficient and the side effects are acceptable, the dose may be increased to the maximum recommended dose of 60 mg. The maximum recommended dosing frequency is one dose every 24 hours.

Route of Administration: Oral

In Vitro Use Guide

Effect of dapoxetine on Kv channels using freshly isolated coronary arterial smooth muscle cells was investigated. Whole-cell configuration was used to record Kv currents. Steady-state voltage-dependent inactivation curves were acquired using a two-step protocol. Peak currents were recorded with a 600-ms test potential to +40 mV after 7-s preconditioning steps (from -80 to +30 mV in steps of 10 mV) in the absence and presence of dapoxetine

Name

Type

Language

KUTUB

Preferred Name

English

DAPOXETINE

Official Name

English

DAPOXETINE [MART.]

Common Name

English

Dapoxetine [WHO-DD]

Common Name

English

LY-210448

Code

English

PRILIGY

Brand Name

English

BENZENEMETHANAMINE, N,N-DIMETHYL-.ALPHA.-(2-(1-NAPHTHALENYLOXY)ETHYL)-

Systematic Name

English

(+)-(S)-N,N-DIMETHYL-.ALPHA.-(2-(1-NAPHTHYLOXY)ETHYL)BENZYLAMINE

Systematic Name

English

DAPOXETINE [MI]

Common Name

English

dapoxetine [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C94725